Long-term Safety and Efficacy Study of DX-2930 (SHP643) to Prevent Acute Angioedema Attacks in Patients With Type I and Type II HAE
HELP Study ExtensionTM: An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of DX-2930 for Prevention Against Acute Attacks of Hereditary Angioedema (HAE)
Sponsor: Shire
A PHASE3 clinical study on Hereditary Angioedema (HAE), this trial is completed. The trial is conducted by Shire and has accumulated 14 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
14 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Sep 2021 [monthly]
Completed PHASE3
▶ Show 9 earlier versions
-
Jun 2020 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2020 — Jun 2020 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
May 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE3
-
Jun 2018 — May 2019 [monthly]
Active Not Recruiting PHASE3
-
Feb 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Nov 2017 — Feb 2018 [monthly]
Active Not Recruiting PHASE3
-
Mar 2017 — Nov 2017 [monthly]
Active Not Recruiting PHASE3
Status: Enrolling By Invitation → Active Not Recruiting
-
Feb 2017 — Mar 2017 [monthly]
Enrolling By Invitation PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Enrolling By Invitation PHASE3
First recorded
May 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Shire
For direct contact, visit the study record on ClinicalTrials.gov .